CJC-1295 Without DAC

Overview

CJC-1295 Without DAC, often referred to as Modified GRF (1-29), is a synthetic peptide designed to stimulate the natural release of growth hormone (GH) from the pituitary gland. Unlike the DAC-modified version, CJC-1295 Without DAC has a significantly shorter half-life, resulting in a more physiologic and pulsatile growth hormone release pattern.

This peptide is widely studied in research involving growth hormone regulation, recovery, body composition, and metabolic function.

Mechanism of Action

CJC-1295 Without DAC binds to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, promoting the release of endogenous growth hormone. This may lead to:

• Increased natural growth hormone secretion.
• Elevated insulin-like growth factor-1 (IGF-1) production.
• Enhanced protein synthesis.
• Support for tissue repair and recovery.
• Improved metabolic regulation.
• Promotion of normal growth hormone pulsatility.

Because it lacks the Drug Affinity Complex (DAC), its activity is shorter in duration compared to CJC-1295 with DAC.

Research Applications

CJC-1295 Without DAC has been investigated in:

• Growth hormone physiology studies.
• Healthy aging research.
• Exercise recovery investigations.
• Body composition research.
• Metabolic health studies.
• Sleep and recovery research.
• Endocrine function studies.

Potential Effects Observed in Studies

Research has suggested that CJC-1295 Without DAC may:

• Support natural growth hormone release.
• Increase IGF-1 levels.
• Promote recovery from physical stress.
• Support lean muscle maintenance.
• Enhance fat metabolism.
• Improve sleep quality and recovery processes.
• Support healthy metabolic function.

Individual responses may vary depending on study conditions and biological factors.

Possible Side Effects

Reported side effects may include:

• Injection-site irritation.
• Headache.
• Flushing.
• Mild dizziness.
• Fatigue.
• Temporary water retention.
• Tingling sensations.

Most effects are generally mild and transient.

Advantages Compared to DAC Version

Potential characteristics of the non-DAC version include:

• Shorter duration of action.
• More physiologic growth hormone pulses.
• Greater flexibility in dosing protocols.
• Reduced prolonged exposure to elevated growth hormone levels.

These characteristics have made it a popular choice in research focused on mimicking natural hormone release patterns.

Precautions

• Long-term safety continues to be evaluated.
• Growth hormone and IGF-1 levels may require monitoring in research settings.
• Product quality and purity can vary among manufacturers.
• Appropriate scientific and medical oversight is recommended.

Storage

• Typically supplied as a lyophilized (freeze-dried) peptide powder.
• Store refrigerated according to manufacturer recommendations.
• Protect from heat, moisture, and direct sunlight.
• Refrigerate after reconstitution.
• Avoid repeated freeze-thaw cycles.

Packaging

Common Product Formats:

• 2 mg vials.
• 5 mg vials.
• 10 mg vials.
• Research-grade peptide formulations.

Summary

CJC-1295 Without DAC (Modified GRF 1-29) is a short-acting growth hormone-releasing hormone analog designed to stimulate the body’s natural production of growth hormone. Its shorter half-life allows for a more physiologic pattern of hormone release, making it a widely studied peptide in research involving recovery, body composition, metabolic health, and healthy aging.